Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 10/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 10/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 5/20 | 0.43 |
| ▸ | HTR2C | P28335 | 5/20 | 0.43 |
| ▸ | HTR2B | P41595 | 4/20 | 0.43 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30200200 | 1.00 | SLC6A2 (0.46) | SLC6A2SLC6A4SLC6A3MEN1ALDH1A1 | |
| SCHEMBL2904519 | 0.98 | SLC6A2 (0.45) | SLC6A2SLC6A4SLC6A3MEN1ALDH1A1 | |
| SCHEMBL4436450 | 0.85 | SLC6A4 (0.45) | SLC6A2SLC6A4SLC6A3HTR2AKCNH2 | |
| SCHEMBL4625651 | 0.83 | SLC6A4 (0.49) | SLC6A2SLC6A4SLC6A3MEN1ALDH1A1 | |
| SCHEMBL28580037 | 0.82 | KCNH2 (0.43) | SLC6A2SLC6A4SLC6A3MEN1ALDH1A1 | |
| SCHEMBL7376502 | 0.82 | USP2 (0.41) | MEN1ALDH1A1POLBHPGDKMT2A | |
| SCHEMBL321697 | 0.81 | KDM4E (0.53) | SLC6A2SLC6A4SLC6A3MEN1ALDH1A1 | |
| SCHEMBL30785121 | 0.81 | KDM4E (0.53) | SLC6A2SLC6A4SLC6A3MEN1ALDH1A1 | |
| SCHEMBL2904522 | 0.80 | SLC6A2 (0.44) | SLC6A2SLC6A4SLC6A3MEN1ALDH1A1 | |
| SCHEMBL10148127 | 0.80 | HTR2A (0.50) | SLC6A2SLC6A4SLC6A3MEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12410142-B2 | Substituted imidazole salt compounds, preparation method thereof, pharmaceutical composition thereof and application thereof | XIAMEN VIVOHEALTHS TECHNOLOGY CO., LTD. (CN) | 2025-09-09 | — | — | US | disclosed |
| EP-3608312-B1 | SUBSTITUTED IMIDAZOLE SALT COMPOUNDS, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND APPLICATIONS THEREOF | XIAMEN VIVOHEALTHS TECH CO LTD (CN) | 2024-06-26 | — | — | EP | disclosed |
| US-20230202986-A1 | SUBSTITUTED IMIDAZOLE SALT COMPOUNDS, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION THEREOF AND APPLICATION THEREOF | XIAMEN VIVOHEALTHS TECHNOLOGY CO., LTD. (CN) | 2023-06-29 | — | — | US | disclosed |
| CN-111971287-B | Macrocyclic compounds as TRK kinase inhibitors | 重庆复尚源创医药技术有限公司 | 2023-06-02 | — | — | CN | disclosed |
| US-11584722-B2 | Substituted imidazole salt compounds, preparation method thereof, pharmaceutical composition thereof and application thereof | XIAMEN VIVOHEALTHS TECHNOLOGY CO., LTD. (CN) | 2023-02-21 | — | — | US | disclosed |
| US-11555042-B2 | Macrocyclic compounds as TRK kinases inhibitors | FOCHON BIOSCIENCES, LTD. (CN) | 2023-01-17 | — | — | US | disclosed |
| CN-115594669-A | Fused ring derivative and preparation method and medical application thereof | 深圳信立泰药业股份有限公司（CN） | 2023-01-13 | — | — | CN | disclosed |
| US-20220242828-A1 | SUBSTITUTED FLUORINE-CONTAINING IMIDAZOLE SALT COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | XIAMEN VIVOHEALTHS TECH CO LTD (CN) | 2022-08-04 | — | — | US | disclosed |
| EP-3967683-A1 | SUBSTITUTED FLUORINE-CONTAINING IMIDAZOLE SALT COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | Xiamen Vivohealths Technology Co., Ltd. (CN) | 2022-03-16 | — | — | EP | disclosed |
| CN-113966325-A | Fluorine-containing substituted imidazole salt compound, preparation method thereof, medicinal composition and application thereof | 厦门华绰生物医药科技有限公司 | 2022-01-21 | — | — | CN | disclosed |
| EP-1888505-A1 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2008-02-20 | — | — | EP | disclosed |
| US-20070083046-A1 | Morpholine derivatives as norepinephrine reuptake inhibitors | ELI LILLY AND COMPANY (US) | 2007-04-12 | — | — | US | disclosed |
| US-20070060585-A1 | Morpholine derivatives as norepinephrine reuptake inhibitors | ELI LILLY AND COMPANY | 2007-03-15 | — | — | US | disclosed |
| US-20070060585-A1 | Morpholine derivatives as norepinephrine reuptake inhibitors | ELI LILLY AND COMPANY | 2007-03-15 | — | — | US | disclosed |
| US-20070060585-A1 | Morpholine derivatives as norepinephrine reuptake inhibitors | ELI LILLY AND COMPANY | 2007-03-15 | — | — | US | disclosed |
| WO-2006125593-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2006-11-30 | — | — | WO | disclosed |
| EP-1716126-A1 | MORPHOLINE DERIVATIVES AS NOREPINEPHRINE REUPTAKE INHIBITORS | ELI LILLY AND COMPANY (US) | 2006-11-02 | — | — | EP | disclosed |
| EP-1682523-A1 | MORPHOLINE DERIVATIVES AS NOREPINEPHRINE REUPTAKE INHIBITORS | ELI LILLY AND COMPANY (US) | 2006-07-26 | — | — | EP | disclosed |
| WO-2005066144-A1 | MORPHOLINE DERIVATIVES AS NOREPINEPHRINE REUPTAKE INHIBITORS | ELI LILLY AND COMPANY (US) | 2005-07-21 | — | — | WO | disclosed |
| WO-2005047272-A1 | MORPHOLINE DERIVATIVES AS NOREPINEPHRINE REUPTAKE INHIBITORS | ELI LILLY AND COMPANY (US) | 2005-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060585-A1 | Morpholine derivatives as norepinephrine reuptake inhibitors | SLC6A2, SLC18A2, SLC6A3 | SLC6A2 1/4885SLC6A4 4/4885SLC6A3 3/4885 |
| US-20070083046-A1 | Morpholine derivatives as norepinephrine reuptake inhibitors | SLC6A2, SLC18A2, SLC6A3 | SLC6A2 1/4885SLC6A4 4/4885SLC6A3 3/4885 |
| US-12410142-B2 | Substituted imidazole salt compounds, preparation method thereof, pharmaceutical composition thereof and application thereof | ALDOA, IDE, ACAT1 | SLC6A2 175/4885SLC6A4 754/4885SLC6A3 238/4885 |
| US-11584722-B2 | Substituted imidazole salt compounds, preparation method thereof, pharmaceutical composition thereof and application thereof | ALDOA, IDE, ACAT1 | SLC6A2 175/4885SLC6A4 754/4885SLC6A3 238/4885 |
| US-11555042-B2 | Macrocyclic compounds as TRK kinases inhibitors | PLK2, ERBB3, DMPK | SLC6A2 4577/4885SLC6A4 4223/4885SLC6A3 4436/4885 |
| US-20220242828-A1 | SUBSTITUTED FLUORINE-CONTAINING IMIDAZOLE SALT COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | PRKAG1, GPR119, PRKAG2 | SLC6A2 1234/4885SLC6A4 1781/4885SLC6A3 1061/4885 |
| US-20230202986-A1 | SUBSTITUTED IMIDAZOLE SALT COMPOUNDS, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION THEREOF AND APPLICATION THEREOF | ALDOA, IDE, ACAT1 | SLC6A2 175/4885SLC6A4 754/4885SLC6A3 238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.